Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000094" target="_blank" >RIV/00064190:_____/19:N0000094 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/19:10383045 RIV/00216208:11140/19:10383045 RIV/00216208:11150/19:10383045 RIV/65269705:_____/19:00070834 and 4 more

Result on the web

<a href="https://www.termedia.pl/Real-world-effectiveness-and-safety-of-omalizumab-in-patients-with-uncontrolled-severe-allergic-asthma-from-the-Czech-Republic,7,33119,1,1.html" target="_blank" >https://www.termedia.pl/Real-world-effectiveness-and-safety-of-omalizumab-in-patients-with-uncontrolled-severe-allergic-asthma-from-the-Czech-Republic,7,33119,1,1.html</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5114/ada.2018.76606" target="_blank" >10.5114/ada.2018.76606</a>

Result language

angličtina

Original language name

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Original language description

Introduction: This was a sub-group analysis of patients with uncontrolled persistent allergic asthma (AA) in the healthcare setting of the Czech Republic, from a global non-interventional, 2-year post-marketing, observational eXpeRience registry. Aim: To evaluate the real-life effectiveness and safety of omalizumab. Material and methods: Patients with uncontrolled persistent AA (currently defined by the Global Initiative for Asthma (GINA) as uncontrolled severe AA) who started omalizumab treatment 15 weeks before inclusion in the registry were analysed for physicians' global evaluation of treatment effectiveness (GETE), asthma symptoms, corticosteroid use, exacerbation rate, asthma control, quality of life, healthcare utilisation and safety during a 24-month observation period. Results: One hundred and fourteen patients from the Czech Republic were enrolled in the eXpeRience registry. A total of 88.9% of the patients were evaluated as responders to omalizumab according to the GETE assessment at week 16. From baseline to month 24: mean change in forced expiratory volume in 1 s (FEV1) was 137 ml and the daily dose of OCS decreased (11.6 mg to 6.4 mg prednisolone equivalent); the percentage of patients with no severe clinically significant exacerbations increased (29.5% to 95.1%); Asthma Control Test scores improved (12.4 to 17.3) and mean total number of days of asthma-related medical healthcare use decreased (6.8 days to 0.4 days). Conclusions: The results of this subgroup analysis support the evidence that add-on omalizumab therapy is effective and well tolerated for management of patients with uncontrolled persistent AA in the Czech Republic. Global evaluation of treatment effectiveness assessment is a reliable predictor of long-term response to omalizumab treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30225 - Allergy

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

POSTEPY DERMATOLOGII I ALERGOLOGII

ISSN

1642-395X

e-ISSN

—

Volume of the periodical

36

Issue of the periodical within the volume

1

Country of publishing house

PL - POLAND

Number of pages

10

Pages from-to

34-43

UT code for WoS article

000459758500006

EID of the result in the Scopus database

2-s2.0-85062551297